Couplings of N=1 chiral spinor multiplets

We derive the action for chiral spinor multiplets coupled to vector and scalar multiplets. We give the component form of the action, which contains gauge invariant mass terms for the antisymmetric tensors in the spinor superfield and additional Green-Schwarz couplings to vector fields. We observe that supersymmetry provides mass terms for the scalars in the spinor multiplet which do not arise from eliminating an auxiliary field. We construct the dual action by explicitly performing the duality transformations in superspace and give its component form.Comment: 17 pages, v2 small change

Gaugino Condensation with S-Duality and Field-Theoretical Threshold Corrections

We study gaugino condensation in the presence of an intermediate mass scale in the hidden sector. S-duality is imposed as an approximate symmetry of the effective supergravity theory. Furthermore, we include in the K\"ahler potential the renormalization of the gauge coupling and the one-loop threshold corrections at the intermediate scale. It is shown that confinement is indeed achieved. Furthermore, a new running behaviour of the dilaton arises which we attribute to S-duality. We also discuss the effects of the intermediate scale, and possible phenomenological implications of this model.Comment: 19 pages, LaTeX, 3 postscript figures include

Calabi-Yau Fourfolds with Flux and Supersymmetry Breaking

In Calabi-Yau fourfold compactifications of M-theory with flux, we investigate the possibility of partial supersymmetry breaking in the three-dimensional effective theory. To this end, we place the effective theory in the framework of general N=2 gauged supergravities, in the special case where only translational symmetries are gauged. This allows us to extract supersymmetry-breaking conditions, and interpret them as conditions on the 4-form flux and Calabi-Yau geometry. For N=2 unbroken supersymmetry in three dimensions we recover previously known results, and we find a new condition for breaking supersymmetry from N=2 to N=1, i.e. from four to two supercharges. An example of a Calabi-Yau hypersurface in a toric variety that satisfies this condition is provided.Comment: 26 page

One-Loop Pauli-Villars Regularization of Supergravity I: Canonical Gauge Kinetic Energy

It is shown that the one-loop coefficients of on-shell operators of standard supergravity with canonical gauge kinetic energy can be regulated by the introduction of Pauli-Villars chiral and abelian gauge multiplets, subject to a condition on the matter representations of the gauge group. Aspects of the anomaly structure of these theories under global nonlinear symmetries and an anomalous gauge symmetry are discussed.Comment: 46 pages, full postscript also available from http://phyweb.lbl.gov/theorygroup/papers/preprints.html/41981.ps . Misprints and errors in equations present in the original version have been correcte

One-loop Regularization of Supergravity II: The Dilaton and the Superfield Formulation

The on-shell regularization of the one-loop divergences of supergravity theories is generalized to include a dilaton of the type occurring in effective field theories derived from superstring theory, and the superfield structure of the one-loop corrections is given. Field theory anomalies and quantum contributions to soft supersymmetry breaking are discussed. The latter are sensitive to the precise choice of couplings that generate Pauli-Villars masses, which in turn reflect the details of the underlying theory above the scale of the effective cut-off. With a view to the implementation the Green-Schwarz and other mechanisms for canceling field theory anomalies under a U(1) gauge transformation and under the T-duality group of modular transformations, we show that the K\"ahler potential renormalization for the untwisted sector of orbifold compactification can be made invariant under these groups.Comment: 46 pages, full postscript also available from http://phyweb.lbl.gov/theorygroup/papers/43259.p

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. In this multicentre phase I dose escalation study, 71 patients with refractory solid tumours were enroled into 14 days on/7 days off (noncontinuous dosing) or continuous dosing groups to receive telatinib two times daily (BID). Hypertension (23%) and diarrhoea (7%) were the most frequent study drug-related adverse events of CTC grade 3. The maximum-tolerated dose was not reached up to a dose of 1500 mg BID continuous dosing. Telatinib was rapidly absorbed with median tmax of 3 hours or less. Geometric mean Cmax and AUC0−12 increased in a less than dose-proportional manner and plateaued in the 900–1500 mg BID dose range. Two renal cell carcinoma patients reached a partial response. Tumour blood flow measured by contrast-enhanced magnetic resonance imaging and sVEGFR-2 plasma levels decreased with increasing AUC0−12 of telatinib. Telatinib is safe and well tolerated up to a dose of 1500 mg BID continuous dosing. Based on pharmacokinetic and pharmacodynamic criteria, 900 mg telatinib BID continuously administered was selected as the recommended phase II dose

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes

Maintaining the integrity of sperm DNA is vital to reproduction and male fertility. Sperm contain a number of molecules and pathways for the repair of base excision, base mismatches and DNA strand breaks. The presence of Poly (ADP-ribose) polymerase (PARP), a DNA repair enzyme, and its homologues has recently been shown in male germ cells, specifically during stage VII of spermatogenesis. High PARP expression has been reported in mature spermatozoa and in proven fertile men. Whenever there are strand breaks in sperm DNA due to oxidative stress, chromatin remodeling or cell death, PARP is activated. However, the cleavage of PARP by caspase-3 inactivates it and inhibits PARP's DNA-repairing abilities. Therefore, cleaved PARP (cPARP) may be considered a marker of apoptosis. The presence of higher levels of cPARP in sperm of infertile men adds a new proof for the correlation between apoptosis and male infertility. This review describes the possible biological significance of PARP in mammalian cells with the focus on male reproduction. The review elaborates on the role played by PARP during spermatogenesis, sperm maturation in ejaculated spermatozoa and the potential role of PARP as new marker of sperm damage. PARP could provide new strategies to preserve fertility in cancer patients subjected to genotoxic stresses and may be a key to better male reproductive health